Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Pain Therapeutics (NASDAQ:PTIE) Share Price
Media stories about Pain Therapeutics (NASDAQ:PTIE) have trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pain Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 47.3396548555042 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Stock Indicator Focus for Pain Therapeutics (PTIE) – Financial News Review (finnewsreview.com)
- Pain Therapeutics (PTIE) Posts Earnings Results, Misses Expectations By $0.17 EPS (americanbankingnews.com)
- Pain Therapeutics Reports Q2 2017 Financial Results And Mid-year Corporate Update (finance.yahoo.com)
- Pain Therapeutics reports 2Q loss (finance.yahoo.com)
Shares of Pain Therapeutics (PTIE) opened at 3.39 on Tuesday. Pain Therapeutics has a one year low of $3.10 and a one year high of $21.00. The stock has a 50 day moving average price of $3.68 and a 200-day moving average price of $2.25. The company’s market capitalization is $22.34 million.
Pain Therapeutics (NASDAQ:PTIE) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.47) by $0.17. On average, equities research analysts expect that Pain Therapeutics will post $1.51 EPS for the current year.
A number of analysts have recently commented on the company. Zacks Investment Research upgraded Pain Therapeutics from a “sell” rating to a “buy” rating and set a $4.00 price target on the stock in a report on Thursday, July 20th. Gabelli lowered Pain Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, July 17th. Finally, ValuEngine lowered Pain Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.
About Pain Therapeutics
Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.
Receive News & Stock Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related stocks with our FREE daily email newsletter.